Zealand Pharma A/s · OMXCOP:ZEAL
Zealand Pharma A/s — Q1 2020 Earnings Presentation
13 slides from Zealand Pharma A/s's earnings presentation, May 15, 2020
Slide 1: Interim report for the first quarter of 2020
Interim report for the first quarter of 2020 Zealand Pharma May 14, 2020
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains information pertaining to Zealand Pharma A/S (“Zealand"). Neither Zealand nor its management, directors, employees or representatives make any representation or warranty, express or implied, as to the accuracy or completeness of any of the inform
Slide 3: Building U.S. operations while continuing to advance our pipeline
Building U.S. operations while continuing to advance our pipeline Filed New Drug Application with the U.S. FDA for the dasiglucagon HypoPal® rescue pen to treat severe hypoglycemia Announced positive topline results from a Phase 2 clinical trial with dasiglucagon in individuals who have undergone ga
Slide 4: Progressing our business initiatives despite circumstances created by COVID-19
Progressing our business initiatives despite circumstances created by COVID-19 engagement 4 HCP and patient Staying connected with health care providers and patients with a higher-service sales and marketing model leveraging virtual meetings, training and support Clinical trials Already enrolled pat
Slide 5: Income statement
Income statement Exchange rates used: March 31, 2020 = 6.8158 and December 31, 2019 = 6.6759 5 DKK thousand Q1 2020 Q1 2019 Revenue Royalty expenses Research and development expenses Administrative expenses Other operating income Operating result Net financial items Result before tax Tax 12,417 0 -1
Slide 6: A strong financial position to support our growing business
A strong financial position to support our growing business Net Operating Expenses DKK 171.0 million / USD 25.1 million Cash position DKK 1.29 billion / USD 189.4 million R&D and Administrative Expenses DKKm Cash and cash equivalents, restricted cash and securities DKKm $m 103 $m 235 1.600 700 1.400
Slide 7: 2020 financial guidance
2020 financial guidance The increase in guidance compared to the prior guidance for 2020 of DKK 790-810 million is due to the completion of the asset purchase agreement for Valeritas, which closed on April 2, 2020, and increased Zealand Pharma by 110 employees in the United States and added the V-Go
Slide 8: Our robust pipeline of next generation peptide therapeutics
Our robust pipeline of next generation peptide therapeutics Dasiglucagon S.C. Continuous Infusion Congenital hyperinsulinism Dasiglucagon Adjustable Mini-Dose Post bariatric hypoglycemia 1 NDA Submitted March 2020; 2 Partnered with Boehringer Ingelheim. Zealand eligible for EUR 365m in outstanding m
Slide 9: Multiple opportunities to improve patients' lives with dasiglucagon via different product modalities
We are pursuing multiple opportunities to improve modalities patients’ lives with dasiglucagon via different product Dasiglucagon Novel stable glucagon analog Fast onset-of-action Unique stability in liquid formulation HypoPal® rescue pen for severe hypoglycemia Infusion pump therapy for recurrent l
Slide 10: Positive topline results from Phase 2 trial with dasiglucagon after bariatric surgery
Positive topline results from Phase 2 trial with dasiglucagon in individuals who have undergone bariatric surgery Recurrent episodes of serious hypoglycemia are experienced after meals by a subset of individuals who have had gastric bypass bariatric surgery Time spent in post-meal hypoglycemia (plas
Slide 11: Advancing two promising programs for short bowel syndrome
Advancing two promising programs to address severe unmet medical needs for patients with short bowel syndrome Glepaglutide GLP-2 analog ZP 7570 GLP-1R/GLP-2R dual agonist Pivotal Phase 3 • Evaluate once-and twice-weekly glepaglutide dosing over 24 weeks • Results expected H2 2021 Phase 1a • • • Sing
Slide 12: A strong first quarter, focus on U.S. operations and clinical trials
A strong first quarter, focus on U.S. operations and clinical trials Filed FDA New Drug Acquisition of Valeritas Application for asiglucagon ypoPal® Rescue Pen evere hypoglycemia) Phase 3 initiation for dual hormonal artificial pancreas with dasiglucagon (automated diabetes management) Phase 3 resul
Slide 13: Q&A
Q&A Q1 Road Show, Copenhagen and virtual – May 18 & 20 Bryan Garnier Growth Conference – May 19 AktieInfo Investo Event – May 26 Jefferies Global Healthcare Conference – June 4 Goldman Sachs 41st Annual Global Healthcare Conference – June 10 Citi European Healthcare Conference – June 16-17 13